Breaking News

Sorrento Appoints Translational Medicine SVP

April 8, 2014

Walters brings 15 years of drug development and business experience

Ian B. Walters, M.D., has been appointed senior vice president of translational medicine and corporate development at Sorrento Therapeutics, Inc. Dr. Walters has more than 15 years of drug development and business experience in both small biopharma and big pharma companies. He joins the company from Bristol Myers Squibb, where he led oncology drug development programs, large international matrix teams, and strategic transactions.  
Dr. Walters spent seven years with BMS, most recently working with the Strategic Transactions Group to evaluate and execute licensing agreements, mergers and acquisitions, clinical collaborations, as well as BMS' immune-oncology strategy. Previously he managed physicians and helped oversee the development of oncology compounds, including, Brivanib, YERVOY, SPRYCEL, Nivolimab, and Elotuzumab, as well as biomarker and companion diagnostics.    
"Ian will help drive the advancement of our pipeline, work with our senior management team on strategic transactions, and help to prioritize and advance our assets to the clinic," said Henry Ji, Ph.D., president and chief executive officer of Sorrento.